TY  - JOUR
AU  - Goldman, Jonathan W
AU  - Mazieres, Julien
AU  - Barlesi, Fabrice
AU  - Dragnev, Konstantin H
AU  - Koczywas, Marianna
AU  - Göskel, Tuncay
AU  - Cortot, Alexis B
AU  - Girard, Nicolas
AU  - Wesseler, Claas
AU  - Bischoff, Helge
AU  - Nadal, Ernest
AU  - Park, Keunchil
AU  - Lu, Shun
AU  - Taus, Alvaro
AU  - Cobo, Manuel
AU  - Estrem, Shawn T
AU  - Wijayawardana, Sameera R
AU  - Turner, Kellie
AU  - Oakley, Gerard Joseph
AU  - Hurt, Karla C
AU  - Chiang, Alan Y
AU  - Hossain, Anwar M
AU  - John, William J
AU  - Paz-Ares, Luis
PY  - 2020
DO  - 10.3389/fonc.2020.578756
SN  - 2234-943X
UR  - https://hdl.handle.net/10668/26828
T2  - Frontiers in oncology
AB  - JUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, with erlotinib in patients with non-small cell lung cancer (NSCLC) harboring a Kirsten rat sarcoma (KRAS) mutation. JUNIPER was a Phase...
LA  - en
PB  - Frontiers Research Foundation
KW  - KRAS
KW  - NSCLC
KW  - Abemaciclib
KW  - Erloitinib
KW  - Platinum-resistant
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Erlotinib Hydrochloride
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Juniperus
KW  - Immune Checkpoint Inhibitors
KW  - Progression-Free Survival
TI  - A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
TY  - research article
VL  - 10
ER  -